ELDN · Eledon Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $66.27M | $51.96M | $30.31M | $27.08M | $23.73M | $6.13M |
| SG&A | $16.98M | $18.61M | $12.69M | $12.70M | $13.13M | $10.05M |
| Total Operating Expenses | $83.25M | $70.58M | $43.00M | $88.43M | $36.87M | $18.46M |
| D&A | - | - | - | - | - | $5.0K |
| Operating Income | ($45.58M) | ($35.75M) | ($43.00M) | ($88.43M) | ($36.87M) | ($18.46M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $35.0K | $431.0K | $0 | $0 | ($2.35M) | ($404.0K) |
| Net Income | ($45.62M) | ($36.18M) | ($40.33M) | ($87.97M) | ($34.51M) | ($22.81M) |
| EPS - Basic | ($0.52) | ($0.75) | ($1.64) | ($2.33) | - | - |
| EPS - Diluted | ($0.52) | ($0.75) | ($1.64) | ($6.16) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $22.81M | $20.55M | $4.61M | $56.41M | $84.83M | $114.19M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $3.63M | $5.83M | $967.0K | $2.20M | $1.81M | $1.37M |
| Current Assets | $135.69M | $143.73M | $56.13M | $59.52M | $88.35M | $115.63M |
| Total Assets | $169.01M | $177.41M | $89.07M | $92.79M | $170.55M | $197.19M |
| Current Liabilities | $18.34M | $11.58M | $3.90M | $6.47M | $4.40M | $2.48M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $32.23M | $59.27M | $5.65M | $8.61M | $6.55M | $6.59M |
| Stockholders' Equity | $81.08M | $118.14M | $83.42M | $84.18M | $164.00M | $190.60M |
| Retained Earnings | ($401.20M) | ($355.59M) | ($243.19M) | ($202.87M) | ($114.90M) | ($80.39M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($62.34M) | ($47.27M) | ($39.53M) | ($28.42M) | ($28.91M) | ($15.21M) |
| Investing Cash Flow | $10.79M | ($70.31M) | ($45.29M) | - | - | $11.04M |
| Financing Cash Flow | $53.81M | $133.52M | $33.02M | - | ($449.0K) | $109.58M |
| CapEx | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -27.0% | -20.4% | -45.3% | -94.8% | -20.2% | -11.6% |
| Return on equity | -56.3% | -30.6% | -48.3% | -104.5% | -21.0% | -12.0% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 7.40 | 12.42 | 14.41 | 9.19 | 20.07 | 46.57 |
| Quick ratio | 7.40 | 12.42 | 14.41 | 9.19 | 20.07 | 46.57 |
| Cash ratio | 1.24 | 1.77 | 1.18 | 8.71 | 19.28 | 45.99 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 2.08 | 1.50 | 1.07 | 1.10 | 1.04 | 1.03 |
| Liabilities / Assets | 0.19 | 0.33 | 0.06 | 0.09 | 0.04 | 0.03 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 1.5x | 1.7x | 0.5x | 0.4x | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -27.5% | 16.9% | 51.4% | -139.9% | -99.7% | -15.0% |
| Net income growth (YoY) | -26.1% | 10.3% | 54.2% | -154.9% | -51.3% | -42.5% |
| EPS growth (YoY) | 30.7% | 54.3% | 73.4% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -31.4% | 41.6% | -0.9% | -48.7% | -14.0% | 1913.7% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
0/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Eledon Pharmaceuticals against the 5 most active filers in the same SIC group.